162 related articles for article (PubMed ID: 2628501)
1. Comparison of CA 15-3 and CEA in diagnosis and monitoring of breast cancer.
Safi F; Kohler I; Röttinger E; Suhr P; Beger HG
Int J Biol Markers; 1989; 4(4):207-14. PubMed ID: 2628501
[TBL] [Abstract][Full Text] [Related]
2. The value of the tumor marker CA 15-3 in diagnosing and monitoring breast cancer. A comparative study with carcinoembryonic antigen.
Safi F; Kohler I; Röttinger E; Beger H
Cancer; 1991 Aug; 68(3):574-82. PubMed ID: 2065278
[TBL] [Abstract][Full Text] [Related]
3. Use of CA15-3, CEA and prolactin for the primary diagnosis of breast cancer and correlation with the prognostic factors at the time of initial diagnosis.
Arslan N; Serdar M; Deveci S; Ozturk B; Narin Y; Ilgan S; Ozturk E; Ozguven MA
Ann Nucl Med; 2000 Oct; 14(5):395-9. PubMed ID: 11108173
[TBL] [Abstract][Full Text] [Related]
4. Comparison of CA 72-4, CA 19-9 and CEA in the diagnosis and monitoring of gastric cancer.
Safi F; Kuhns V; Beger HG
Int J Biol Markers; 1995; 10(2):100-6. PubMed ID: 7561233
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of serum CA27.29, CA15-3 and CEA in patients with breast cancer.
Hou MF; Chen YL; Tseng TF; Lin CM; Chen MS; Huang CJ; Huang YS; Hsieh JS; Huang TJ; Jong SB; Huang YF
Kaohsiung J Med Sci; 1999 Sep; 15(9):520-8. PubMed ID: 10561976
[TBL] [Abstract][Full Text] [Related]
6. Comparison of a novel assay for breast cancer mucin to CA15-3 and carcinoembryonic antigen.
Daly L; Ferguson J; Cram GP; Hars V; George SL; McCarty KS; Bast RC
J Clin Oncol; 1992 Jul; 10(7):1057-65. PubMed ID: 1607912
[TBL] [Abstract][Full Text] [Related]
7. Intensive post-operative follow-up of breast cancer patients with tumour markers: CEA, TPA or CA15.3 vs MCA and MCA-CA15.3 vs CEA-TPA-CA15.3 panel in the early detection of distant metastases.
Nicolini A; Tartarelli G; Carpi A; Metelli MR; Ferrari P; Anselmi L; Conte M; Berti P; Miccoli P
BMC Cancer; 2006 Nov; 6():269. PubMed ID: 17116247
[TBL] [Abstract][Full Text] [Related]
8. Comparison of circulating CA15-3 and carcinoembryonic antigen levels in patients with breast cancer.
Hayes DF; Zurawski VR; Kufe DW
J Clin Oncol; 1986 Oct; 4(10):1542-50. PubMed ID: 2428949
[TBL] [Abstract][Full Text] [Related]
9. Elevated Levels of Serum Tumor Markers CEA and CA15-3 Are Prognostic Parameters for Different Molecular Subtypes of Breast Cancer.
Shao Y; Sun X; He Y; Liu C; Liu H
PLoS One; 2015; 10(7):e0133830. PubMed ID: 26207909
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of serum CA15-3 determination with CEA and TPA in the post-operative follow-up of breast cancer patients.
Nicolini A; Colombini C; Luciani L; Carpi A; Giuliani L
Br J Cancer; 1991 Jul; 64(1):154-8. PubMed ID: 1854615
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the circulating glycoprotein CA549 in mammary cancer and other malignancies.
Clocchiatti L; De Biasi F; Cartei G; Sibau A; Vigevani E; Signor M; Giovannoni M; Ceschia V; Di Chiara F; Grandis S
Tumori; 1991 Oct; 77(5):395-8. PubMed ID: 1781036
[TBL] [Abstract][Full Text] [Related]
12. The usefulness of CA15.3, mucin-like carcinoma-associated antigen and carcinoembryonic antigen in determining the clinical course in patients with metastatic breast cancer.
Deprés-Brummer P; Itzhaki M; Bakker PJ; Hoek FJ; Veenhof KH; de Wit R
J Cancer Res Clin Oncol; 1995; 121(7):419-22. PubMed ID: 7635872
[TBL] [Abstract][Full Text] [Related]
13. MCA in patients with breast cancer: correlation with CEA and CA15-3.
Molina R; Filella X; Mengual P; Prats M; Zanon G; Daniels M; Ballesta AM
Int J Biol Markers; 1990; 5(1):14-21. PubMed ID: 2230347
[TBL] [Abstract][Full Text] [Related]
14. HER-2 gene amplification, serum nucleosomes, CEA and CA15.3 tumor markers in breast cancer patients.
Zeiwar MM; Zaki SM; Mohammad LA; Zidan AA; El Nagar MR
Egypt J Immunol; 2007; 14(2):29-41. PubMed ID: 20306655
[TBL] [Abstract][Full Text] [Related]
15. The prognostic significance of preoperative tumor marker (CEA, CA15-3) elevation in breast cancer patients: data from the Korean Breast Cancer Society Registry.
Nam SE; Lim W; Jeong J; Lee S; Choi J; Park H; Jung YS; Jung SP; Bae SY
Breast Cancer Res Treat; 2019 Oct; 177(3):669-678. PubMed ID: 31312932
[TBL] [Abstract][Full Text] [Related]
16. The Clinical Significance of sICAM-1 in Differentiating Benign Breast Lesions from Breast Cancer.
Chen C; Chen Q; Dong Y; Liu X
Ann Clin Lab Sci; 2020 Sep; 50(5):650-656. PubMed ID: 33067211
[TBL] [Abstract][Full Text] [Related]
17. The diagnostic value of serum tumor markers CEA, CA19-9, CA125, CA15-3, and TPS in metastatic breast cancer.
Wang W; Xu X; Tian B; Wang Y; Du L; Sun T; Shi Y; Zhao X; Jing J
Clin Chim Acta; 2017 Jul; 470():51-55. PubMed ID: 28457854
[TBL] [Abstract][Full Text] [Related]
18. Comparison of serum CA15-3 and CEA in breast cancer.
Hou MF; Huang TJ; Hsieh JS; Huang YS; Huang CJ; Chan HM; Wang JY; Chen YL; Jong SB; Yang CC
Gaoxiong Yi Xue Ke Xue Za Zhi; 1995 Dec; 11(12):660-6. PubMed ID: 8551526
[TBL] [Abstract][Full Text] [Related]
19. CA15-3 serum levels in breast cancer and other malignancies--correlation with clinical course.
Barak V; Carlin D; Sulkes A; Treves A; Biran S
Isr J Med Sci; 1988; 24(9-10):623-7. PubMed ID: 3204010
[TBL] [Abstract][Full Text] [Related]
20. Elevated serum CA15-3 levels correlate with positive estrogen receptor and initial favorable outcome in patients who died from recurrent breast cancer.
Nishimura R; Nagao K; Miyayama H; Matsuda M; Baba K; Matsuoka Y; Yamashita H
Breast Cancer; 2003; 10(3):220-7. PubMed ID: 12955034
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
